Thursday, October 2, 2025 10/2/2025

Profiling and perturbing the inheritance of drug-induced metabolic states in cancer with Inheritance-Seq

Award Number: R61CA278536
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Profiling and perturbing the inheritance of drug-induced metabolic states in cancer with Inheritance-Seq - Non-genetic acquired resistance has been implicated in the therapy failure of multiple cancer types. Therefore, there have been significant efforts to uncover the mechanisms regulating such drug-resistant cellular states and how these states may be perturbed to promote cancer cell death and curb disease progression. While there has been much progress in understanding and characterizing drug-induced cellular states, little is known about what controls the inheritance of these states by daughter cells. Understanding the heritability of drug-induced states is not only useful to determine dosing frequency but also is critical in designing effective combination treatment regimens. Existing approaches to characterize cell state inheritance fall short of this goal because the features needed to define cell states are inaccessible, the temporal windows needed to observe state transitions are exceedingly long, and the cellular throughput needed to robustly read out effects of systematic perturbation is prohibitively high. Here, we propose inheritance-Seq, a new method that enables quantification of cell state heritability to meet the need for an approach to understand the heritability of drug-induced states. Inheritance-Seq combines CRISPR-based genetic lineage tracing and phenotyping with microscopy and in situ sequencing (ISS) to enable scalable measurement of phenotype inheritance with systematic pooled genetic perturbations to explore the mechanisms of phenotypic trait inheritance in cells. In the proposed work, we will design and implement a general framework to quantify the heritability of cell states and validate the performance of inheritance-Seq by identifying known factors regulating the inheritance of drug-induced metabolic state changes in OVCAR8 cells following carboplatin treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $206,955 )
2025	2025	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Biology Research	001	2	5/30/2025	NON-COMPETING CONTINUATION	$20,695
2025	2025	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Biology Research	000	2	4/7/2025	NON-COMPETING CONTINUATION	$186,260
														Subtotal = $206,955

Issue Date FY: 2024 ( Subtotal = $207,092 )
2024	2024	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Biology Research	000	1	3/27/2024	NEW	$207,092
														Subtotal = $207,092

Grand Total All Awards = $414,047

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Profiling and perturbing the inheritance of drug-induced metabolic states in cancer with Inheritance-Seq

Award Number: R61CA278536

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer